What is Beijing Konruns Pharmaceutical Co.,Ltd.'s (603590.SS) StockRank?

MoatMap's StockRank for Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS) is 33/100, with a Sell signal. This is a composite score combining Quality (61), Value (40), and Momentum (24) factor ranks across MoatMap's 19,000+ stock universe.

Does Beijing Konruns Pharmaceutical Co.,Ltd. have an economic moat?

Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS) has a Quality factor score of 61/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Beijing Konruns Pharmaceutical Co.,Ltd. a buy, hold, or sell?

MoatMap's current signal for Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS) is Sell, based on a StockRank of 33/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Beijing Konruns Pharmaceutical Co.,Ltd. in?

Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

603590.SS

SELLREMOVE

Beijing Konruns Pharmaceutical Co.,Ltd. · Healthcare · China · $810M · Avg Vol: $17M/d

StockRank

P/E (TTM)

28.0x

ROE

4.9%

D/E

0.1x

Dividend %

1.2%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Beijing Konruns Pharmaceutical is a domestic Chinese pharmaceutical company. It does not possess the global CDMO pricing power or the scale economics needed to benefit from our healthcare manufacturing theme.

COMPANY DESCRIPTION

Beijing Konruns Pharmaceutical is a biopharmaceutical company focused on the research, development, and commercialization of innovative drugs, particularly in the fields of oncology and hematology. The company's competitive moat is anchored by its flagship product, 'Sulejia' (hemocoagulase for injection), which holds a dominant market share in China's surgical hemostasis market. It is an innovative, R&D-driven niche player with a robust pipeline of targeted therapies and biological drugs.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	128M	136M	122M	135M	1.8%
EPS	0.10	0.14	0.04	0.16	17.3%
Shares	160M	160M	159M	159M	-0.6%
Debt	2M	22M	31M	47M	195.4%
Equity	432M	452M	465M	475M	3.2%
Op CF	18M	29M	25M	17M	-1.1%
Inv CF	-48M	-66M	-29M	7M	—
Fin CF	-8M	21M	-1M	-3M	—

PRICE (1M)-15.9%

SMA 50SMA 200

$4.40

RSI (14)

6.6

52W High

$10.05

From 52W High

0.4%

SCORE BREAKDOWN

Quality

ROIC

5.4%58.2

ROE

4.9%56.1

GP/Assets

20.2%47.3

Op. Margin

27.8%90.2

FCF/Assets

4.5%69.0

Piotroski

—55.8

Int. Cover

26.2x77.7

D/E Ratio

0.09x66.7

Current Ratio

3.05x53.3

Value

P/E (TTM)

28.0x39.6

EV/EBITDA

21.0x17.2

P/FCF

199.9x46.2

P/B

1.5x67.3

P/S

5.1x40.4

Div Yield

1.2%31.9

Momentum

52W High %

44%16.4

RS 6M

-45%25.5

SMA 50/200

0.82x16.2

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

6%46.9

FUNDAMENTALS

Market Cap

$810M

P/E (Forward)

—

Gross Margin

89.8%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 603590.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
603590.SS	Beijing Konruns Pharmaceutical Co.,Ltd.(you)	$810M	33	SELL
688399.SS	Jiangsu Bioperfectus Technologies Co., Ltd.	$658M	34	SELL
688767.SS	Hangzhou Biotest Biotech Co.,Ltd.	$842M	39	HOLD
301333.SZ	R&G PharmaStudies Co., Ltd.	$724M	38	HOLD
1477.HK	Ocumension Therapeutics	$636M	37	HOLD
688488.SS	Jiangsu Aidea Pharmaceutical Group Co., Ltd.	$965M	28	SELL
301080.SZ	Acrobiosystems Co.,Ltd.	$1.0B	38	HOLD
688293.SS	Shanghai OPM Biosciences Co., Ltd.	$898M	42	HOLD
9966.HK	Alphamab Oncology	$1.1B	29	SELL
688075.SS	Assure Tech (Hangzhou) Co., Ltd.	$643M	27	SELL

Peer medians: ROE 4.7% · P/E 27.6x · Gross margin 53.0%

Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS) — Stock Score Summary

Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS) has a MoatMap StockRank of 33/100 based on Quality (61/100), Value (40/100), and Momentum (24/100) factor scores. The current signal is SELL. Beijing Konruns Pharmaceutical is a domestic Chinese pharmaceutical company. It does not possess the global CDMO pricing power or the scale economics needed to benefit from our healthcare manufacturing theme.

Key Financial Metrics

Price	$4.40
Market Cap	$810M
P/E (TTM)	28.02
Price/Book	1.45
Return on Equity	4.9%
Return on Invested Capital	5.4%
Debt/Equity	9.43
Gross Margin	89.8%
Operating Margin	27.8%
Revenue Growth	1.4%
Dividend Yield	1.2%
Free Cash Flow	$4M

Beijing Konruns Pharmaceutical Co.,Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Beijing Konruns Pharmaceutical Co.,Ltd.’s (603590.SS) StockRank?: MoatMap’s StockRank for Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS) is 33/100, with a Sell signal. It is a composite of Quality (61), Value (40), and Momentum (24) factor ranks across MoatMap’s 19,000+ stock universe.
Does Beijing Konruns Pharmaceutical Co.,Ltd. have an economic moat?: Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS) has a Quality factor score of 61/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Beijing Konruns Pharmaceutical Co.,Ltd. a buy, hold, or sell?: MoatMap’s current signal for Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS) is Sell, based on a StockRank of 33/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Beijing Konruns Pharmaceutical Co.,Ltd. in?: Beijing Konruns Pharmaceutical Co.,Ltd. (603590.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).